ArticleOncoscience2026
Combined hepatocellular-cholangiocarcinoma: A rare and challenging diagnostic entity - A Case Report.
Article in Oncoscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare and aggressive liver cancer, representing 2-5% of primary hepatic malignancies. Its mixed hepatocytic and cholangiocytic features pose major diagnostic challenges, and the absence of standardized treatment guidelines limits effective management. CASE PRESENTATION: A 61-yearold man with type 2 diabetes, hypertension, and chronic hepatitis B presented with right hypochondrial pain. Laboratory tests revealed elevated alpha-fetoprotein (247 ng/mL). Imaging showed a heterogeneous mass in liver segment V with capsular retraction, hilar lymphadenopathy, and atypical enhancement. Histological examination of the CT-guided liver biopsy suggested hepatocellular carcinoma. However, this proved to be a key diagnostic pitfall, as the complete resected specimen revealed a mixed tumor: final diagnosis of combined hepatocellularcholangiocarcinoma (cHCC-CCA) with approximately 20% hepatocellular and 80% cholangiocarcinoma components. Clinical Discussion: This case underscores the limitations of preoperative biopsy in diagnosing cHCC-CCA, highlighting the risk of misdiagnosis. Radiological features often reflect the predominant histological component but can be nonspecific due to tumor heterogeneity. Definitive diagnosis requires thorough histopathological examination with immunohistochemistry.
conclusionscHCC-CCA poses a significant diagnostic and therapeutic challenge. Recognizing this mixed phenotype in complex liver masses is crucial. Histopathological confirmation and complete surgical resection remain key to optimal outcomes. Detailed case reports are essential to improve diagnostic criteria, elucidate molecular biology, and guide evidence-based management for this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.